Charles Schwab Investment Management Inc. Buys 8,869 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Charles Schwab Investment Management Inc. lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 250,346 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,869 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.19% of ANI Pharmaceuticals worth $14,936,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Pacer Advisors Inc. grew its position in ANI Pharmaceuticals by 23,259.8% in the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after purchasing an additional 565,910 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its position in ANI Pharmaceuticals by 17.6% during the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock worth $13,731,000 after purchasing an additional 34,416 shares during the period. Intech Investment Management LLC acquired a new position in shares of ANI Pharmaceuticals in the third quarter valued at $751,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in ANI Pharmaceuticals by 99.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 13,470 shares of the specialty pharmaceutical company’s stock valued at $804,000 after acquiring an additional 6,728 shares during the period. Finally, Global Alpha Capital Management Ltd. lifted its holdings in ANI Pharmaceuticals by 1.8% during the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after purchasing an additional 9,500 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ANIP has been the subject of several analyst reports. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. HC Wainwright reissued a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Piper Sandler began coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price on the stock. Finally, Raymond James increased their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $77.33.

Insider Transactions at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 33,981 shares of company stock worth $1,970,066. Corporate insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $56.97 on Friday. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -103.58 and a beta of 0.73. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The business’s fifty day moving average is $58.05 and its 200 day moving average is $60.43. ANI Pharmaceuticals, Inc. has a 52-week low of $48.20 and a 52-week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. The company had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.05 earnings per share. Research analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.